SCHEMBL5547199

SCHEMBL5547199

O=[N+]([O-])c1cc(Cc2ccc(F)c(F)c2)cnc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 1/20 0.40
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
HIF1A Q16665 1/20 0.36
PIN1 Q13526 4/20 0.36
ALDH3A1 P30838 1/20 0.36
VCAM1 P19320 1/20 0.35
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GAA P10253 2/20 0.34
SNCA P37840 1/20 0.34
SLC29A1 Q99808 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CYP17A1 P05093 1/20 0.33
CYP11B1 P15538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545829 0.84 SNCA (0.40) ALDH1A1MAPTPOLBIDO1TDO2
SCHEMBL5038066 0.81 PIN1 (0.37) ALDH1A1MAPTPOLBPIN1NPC1
SCHEMBL5540831 0.81 ALDH1A1 (0.37) ALDH1A1MAPTPOLBIDO1TDO2
SCHEMBL5538418 0.80 FYN (0.40) ALDH1A1MAPTIDO1TDO2SNCA
SCHEMBL5547391 0.78 LMNA (0.41) ALDH1A1MAPTPOLBIDO1TDO2
SCHEMBL27667089 0.77 CYP4F2 (0.38) ALDH1A1MAPTIDO1TDO2
SCHEMBL27324878 0.76 PIN1 (0.39) ALDH1A1MAPTHIF1APIN1VCAM1
SCHEMBL10366552 0.76 HTT (0.47) ALDH1A1MAPTPOLBPIN1MAPK1
SCHEMBL14880650 0.76 ALDH1A1 (0.60) ALDH1A1MAPTHIF1AALDH3A1VCAM1
Hydrochloric Acid SCHEMBL10365051 0.75 HTT (0.46) ALDH1A1MAPTPOLBPIN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885MAPT 2173/4885POLB 113/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885MAPT 949/4885POLB 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.